US to EU: The Regulatory Roadmap for a First Transatlantic Filing

What actually changes when you cross the Atlantic?

Less of the science than sponsors expect, and more of the structure. The clinical and non-clinical data usually travel well; ICH harmonisation exists precisely so that they do. What does not travel is the legal and personnel architecture around the data. The EU requires a marketing authorisation holder established within the Union, batch certification by a named Qualified Person before any batch is released to the market, and a pharmacovigilance system with a QPPV who resides and operates in the EU or EEA. These are not paperwork items. They are named individuals with personal regulatory accountability, and recruiting or contracting them is a lead-time problem, not a submission-week problem.

In what order should the work happen?

Entity first, then people, then dossier. The legal entity has to exist before it can be named as applicant, and before a QPPV can be appointed to it. The QP and QPPV appointments in turn determine documents inside the dossier and the pharmacovigilance system master file, so appointing them late forces rework. Dossier conversion runs in parallel: an eCTD built for FDA review is not simply re-indexed for the EU, because Module 1 is region-specific and several Module 3 expectations around starting materials and process validation are read more strictly by EU assessors. Sponsors who sequence this the other way round, converting the dossier first and hiring afterwards, are the ones who slip.

Which gaps most often delay a first EU filing?

Four recur. First, no EU entity in place, discovered when the applicant field has to be completed. Second, a QPPV appointed on paper who has neither the authority nor the time to act, which an inspector detects immediately by asking what they actually did last quarter. Third, contract manufacturing agreements that never allocated batch certification responsibility, leaving no one able to release product. Fourth, a paediatric investigation plan not considered early, which is a procedural bar to validation rather than a scientific objection. Each of these is cheap to fix eighteen months out and expensive to fix at submission.

Frequently asked questions

Do we need an EU entity, or can a consultant hold the authorisation?

The marketing authorisation holder must be established in the EU or EEA. A consultancy cannot hold the authorisation on your behalf. What a consultancy can legitimately provide is the QP and QPPV functions, and support in standing the entity up.

Can the same person be our QP and our QPPV?

In principle the roles are distinct and carry different obligations, and in practice combining them is rarely appropriate beyond the very smallest operations. The QP certifies batches; the QPPV owns the pharmacovigilance system. Regulators will probe whether one individual genuinely has capacity for both.

How far ahead should we start?

Plan on twelve to eighteen months before intended submission for the structural work. Entity formation, QP and QPPV recruitment, and quality agreement renegotiation with contract manufacturers are the long poles, and they are sequential rather than parallel.

Sources

1. Directive 2001/83/EC on the Community code relating to medicinal products for human use, European Union. eur-lex.europa.eu
2. Good pharmacovigilance practices (GVP) Module I — Pharmacovigilance systems and their quality systems, European Medicines Agency. ema.europa.eu

Pending scientific review. This briefing summarises published regulatory guidance and has not yet been signed off by a named subject-matter expert. Verify against the primary sources below before relying on it.

Planning a first filing outside your home market?

We act as the bridge between US, EU and Australian requirements, and we supply the QP and QPPV functions the EU obliges you to name.

Explore Regulatory Affairs ➔